BACKGROUND
Tumor metastases in head and neck cancer patients almost invariably heralds a poor prognosis with an average survival of 6 months and treatment of the patients is usually palliative (1) . Five year survival rates for patients with early stage localized head and neck cancers are over 80% but drop to 40% when the disease has spread to the neck nodes, and to below 20% for patients with distant metastatic disease (2) . Uncontrolled cell proliferation and angiogenesis are key characteristics of initiation and early growth of epithelial origin cancers (3) . However, it is the subsequent acquisition of motility and invasiveness that leads to the metastatic dissemination of these tumor cells (4) . Tumor metastasis is a complex process consisting of multiple individual steps (5) . A key process in this metastatic cascade that converts an adherent epithelial cell into a migratory cell, which can invade through the extracellular matrix, is known as epithelialmesenchymal transition (EMT) (6) . Many in vitro and in vivo studies have demonstrated that tumor cells of epithelial origin can acquire mesenchymal phenotype (7, 8) and that these cells are typically seen at the invasive front of primary tumors (4, 9, 10) . The role of EMT in tumor metastasis is further highlighted by the observations that acquisition of mesenchymal markers such as vimentin or S100A4 by epithelial cells is associated with increased metastatic potential (11, 12) .
Functional loss of E-cadherin in epithelial cell has been considered a hallmark of EMT (13) . During tumor progression, E-cadherin can be functionally inactivated or silenced by a number of different mechanisms including somatic mutations (14) , down regulation of gene expression through promoter hypermethylation (15) , histone deacetylation (16) , or transcriptional repression (17) . Several EMT-inducing regulators repress E-cadherin transcription via interaction with specific E-boxes of the proximal E-cadherin promoter (7) . Most prominent E-cadherin regulators are the snail-related zinc-finger transcription factors (snail and slug), (17, 18 ) SIP1/ZEB2, (19) δEF-1/ZEB1 (20) and Twist (21) . Several studies have shown that snail-related transcriptional factors play a transcriptional and regulatory role in invasion, metastasis, and poor outcome for several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC) (16, 22) . Medelsohn et al have recently reported that Snail is an independent marker of tumor metastasis in patients with HNSCC (23) .
A number of studies have highlighted the role of tumor microenvironment in promoting tumor metastasis (24) (25) (26) . We have recently shown that tumor-associated endothelial cells exhibit significantly higher Bcl-2 expression which is directly correlates with metastatic status of head and neck cancer patients (25, 27) . In addition, overexpression of Bcl-2 alone in tumor-associated endothelial cells was sufficient to promote tumor metastasis in a SCID mouse model (25) . We designed this study to understand how these tumor-associated endothelial cells may be promoting EMT in head and neck tumor cells. Our results suggest that endothelial cells expressing Bcl-2 induce EMT-related changes in tumor cells predominantly via the secretion of IL-6. IL-6 is a pleiotropic cytokine that is involved in acute phase of inflammation and is a major inducer of C-reactive protein (28) . Recently, Lederle et al demonstrated that IL-6 promotes malignant growth of skin squamous cell carcinoma by regulating a complex cytokine and protease network (29) . IL-6 is one of main chemokines present in serum samples of head and neck cancer patients and elevated IL-6 levels independently predict tumor recurrence, poor survival and tumor metastasis (30, 31) . However, very little is known about the role of IL-6 in head and neck tumor metastasis and the process of EMT. cell lysate was prepared for Western Blotting. In the immunofluorescence staining experiments, CAL27 cells were cultured on top of cover slips in 6-well plates while the rest of the protocol was same as described above. For IL-6 neutralizing experiments, CAL27 cells were co-cultured with EC-Bcl-2 in presence of neutralizing anti-IL-6 antibody (50 ng/ml)) or isotype control antibody.
ELISA. Endothelial cells, CAL27 or IOE cells were cultured in 6-well plates till they were 80% confluent. Cells were washed and fresh media was added. After 24 hours, culture supernatants were collected from 3 separate experiments and cell number in each well was counted.
Chemokines levels (IL-8, IL-6 and CXCL1/GRO-α) in culture supernatants were measured using Quantikine human ELISA kits (R&D Systems, Minneapolis, MN) as per manufacturer's instructions and normalized to 1x10 Tumor cell motility assay. Tumor cell motility was examined by Xcelligence system using the RTCA DP instrument (Roche, Mannheim, Germany) as per manufacturer's instructions. In brief, 160 µl of media (DMEM for CAL27 cells and K-SFM for IOE) containing 10% FBS was added to the lower chambers. The upper chamber (sensor surface facing down) was then carefully assembled on top of lower chamber and 50 µl of serum free media was added to the wells. After 1 hr of equilibration with media, 100 µl of cell suspension (50,000 cells/well in serum free media) was added to each well. Cell migration to lower chamber was monitored and expressed as cell migration index at 24 hrs.
Tumor metastasis models. CAL27 transduced with vector alone (CAL27-VC) or CAL27-IL-6 (1x10 6 ) and endothelial cells (1x10 6 ) were mixed with 100 µl of Matrigel and injected subcutaneously in the flanks of SCID mice as described previously (25) . Tumor volume measurements began on day 6 and continued twice a week until the end of the study. The length and width of the tumors were measured using a digital caliper and tumor volumes were calculated using the formula, volume (mm 
RESULTS

Bcl-2 expressing endothelial cells (EC-Bcl-2) promote EMT changes via the secretion of IL-
6.
We have previously shown that Bcl-2 expression is significantly elevated in tumor-associated blood vessels of head and neck cancer patients as compared to matched control samples (27) .
Recently, we demonstrated that up-regulation of Bcl-2 in tumor-associated endothelial cells is sufficient to enhance tumor metastasis, in vivo (25) . However, the molecular mechanism by which EC-Bcl-2 promotes tumor metastasis is poorly understood. In this study, we examined if secreted factors from EC-Bcl-2 could induce EMT-related changes in head and neck tumor cells.
Indeed, co-culture of EC-Bcl-2 along with tumor cells (CAL27) markedly enhanced vimentin expression (76% increase) while significantly decreasing E-cadherin expression (52% decrease) in CAL27 cells (Fig. 1A-B) . In addition, co-culture of EC-Bcl-2 with CAL27 also upregulated snail expression, a key repressor of E-cadherin (Fig. 1B) . We next examined the chemokine profile of EC-Bcl-2 cells. Culture supernatants from EC-Bcl-2 cells contained significantly higher levels of IL-8, IL-6 and Gro-α as compared to endothelial cells transduced with vector alone (EC-VC) (Fig. 1C) . To further examine the role of these chemokines in EMT process, CAL27 cells were treated with recombinant IL-8, IL-6, or Gro-α for 3 days and E-cadherin and vimentin levels were analyzed by Western blotting. Interestingly, only IL-6 was able to significantly induce the expression of vimentin (63%) while repressing E-cadherin expression in CAL27 (51%, Fig. 1D ). Similarly, co-culture of CAL27 cells and EC-Bcl-2 in the presence of neutralizing IL-6 antibody significantly reversed IL-6-mediated EMT changes (Fig. 1E-F ). 
IL-6 promotes EMT changes in head and
squamous carcinoma cells, we cultured CAL27 cells for 3 days in the presence or absence of IL-6. IL-6 treatment of CAL27 cells markedly increased vimentin expression (62%) while at the same time decreasing the expression of E-cadherin (61%) ( Fig. 2A-B) . IL-6 treatment also significantly increased snail expression (51%, Fig. 2B) . Similarly, IL-6 treatment of IOE cells significantly upregulated the expression of vimentin (95%) and snail (64%) while reducing the E-cadherin expression (Fig 2C-D) . Next, we examined the IL-6 mediated signaling cascade in CAL27 cells by treating these cells with IL-6 for different time points (0-240 min). IL-6 predominantly activated JAK/STAT3, MAPK, and PI3K/Akt signaling pathways. JAK1/2 activation peaked 10 minutes post IL-6 treatment, whereas STAT3 (pY705 and pS727), ERK1/2 and AKT activation peaked 30 minutes post IL-6 treatment (Fig. 2E ).
IL-6 overexpression in head and neck squamous cells and normal oral epithelial cells
induces EMT changes and enhances tumor cell scattering and motility. To further understand the role of IL-6 in the EMT process, we stably overexpressed IL-6 in CAL27 cells (CAL27-IL-6) and IOE cells (IOE-IL-6) using a retroviral vector. IL-6 expression levels in CAL27 and IOE cells were verified by ELISA and Western blotting. CAL27-IL-6 produced more than 8 fold IL-6 as compared to CAL27 cells transduced by vector alone (CAL27-VC) ( Supplementary Fig. 1A ). CAL27-IL-6 cells also showed significantly higher STAT3 phosphorylation (pY705) as compared to CAL27-VC cells (Supplementary Fig. 1B ) thereby suggesting that IL-6 produced by CAL27-IL-6 cells is biologically active. Interestingly, overexpression of IL-6 in CAL27 was also associated with scattering effect (Fig. 3Aa) , a hallmark of EMT process. In addition, CAL27-IL-6 cells showed significantly higher vimentin (54%) and snail expression (51%) whereas E-cadherin expression was significantly reduced 
(53%, Fig. 3B ). Furthermore, IL-6 overexpression in CAL27 cells significantly enhanced tumor cell migration (Fig. 3C ).
IOE cells produced very low baseline levels of IL-6 and overexpression of IL-6 markedly increased IL-6 production (>30 fold) as compared to IOE-VC (Supplementary Fig. 2A ). Similar to CAL27, IL-6 overexpression induced scattering effect in IOE cells (Fig. 3Da) and significantly increased vimentin (63%) and snail expression (70%) while downregulating Ecadherin levels (77%, Fig. 3E ). In addition, IL-6 overexpression significantly enhanced IOE cell motility (Fig. 3F ).
IL-6 mediates EMT via the activation of JAK-STAT3-snail pathway.
Our signaling experiments showed that IL-6 activates 3 distinct signaling pathways: JAK/STAT3, MAPK, and PI3K/Akt (Fig. 2E) . To examine which of these pathways is used by IL-6 to mediate its EMTrelated effects, we knocked down Akt, STAT3, and ERK1/2 in CAL27 and IOE cells by siRNA treatment. Down regulation of Akt, STAT3, and ERK1/2 protein levels were verified by Western blotting (Fig. 4A-B) . Knocking down of STAT3 in CAL27-IL-6 ( Fig. 4A and C) and IOE-IL-6 cells ( Fig. 4B and D) significantly reversed IL-6 mediated upregulation of vimentin (52% and 48% in CAL27-IL-6 and IOE-IL-6 respectively) and snail protein levels (58% and 64%), whereas Akt and ERK knock down did not significantly alter vimentin and snail levels.
Similarly, STAT3 knock down significantly reversed IL-6-mediated loss of E-cadherin expression (67% and 45%), while Akt knock down had no effect and ERK knock down had only partial effect on E-cadherin expression (Fig. 4) . 6 mediated tumor cell and IOE cell migration. As observed with EMT changes, knocking down of STAT3 significantly decreased CAL27-IL-6 and IOE-IL-6 cell migration ( Fig. 5A and C) .
Knocking down of ERK had partial effect while Akt knock down had the least effect on CAL27 and IOE cell migration (Fig. 5A and C) . To further understand how STAT3 knock down may be inhibiting CAL27 and IOE motility, we examined the activation profile of focal adhesion kinase (FAK), a key player in cell migration. Interestingly, STAT3 knockdown in CAL27-IL-6 and IOE-IL-6 cells markedly reduced FAK phosphorylation whereas Akt and ERK knockdown had no effect on FAK activation ( Fig. 5B and D) .
IL-6 promotes tumor growth, EMT and tumor metastasis, in vivo.
To further investigate the role of IL-6 in EMT process and tumor metastasis, we used a SCID mouse xenograft model. CAL27-IL-6 tumors showed a moderate but significant increase in tumor growth as compared to CAL27-VC cells (Fig. 6A) . CAL27-IL-6 tumor cells exhibited fibroblastic morphology (spindle shape) in contrast to cobblestone morphology of CAL27-VC cells (Fig. 6B) . In addition, CAL27-IL-6 tumors showed markedly elevated levels of activated STAT3 (pY705, Fig. 6C ) and snail proteins (Fig. 6D ) that were predominantly localized in the nucleus. CAL27-IL-6 tumors also showed decreased E-cadherin and increased vimentin expression (Fig. 6E-F) .
Lymph nodes from animals carrying CAL27-VC tumors were negative for metastatic disease whereas 60% of lymph nodes from animals carrying CAL27-IL-6 tumors were positive for metastatic disease (Fig. 7A-C) . Similarly, lungs from animals with CAL27-IL-6 tumors showed marked increase in metastatic nodes (Fig. 7D-E) . 
DISCUSSION
EMT is an important biological process that plays a critical role in tumor cell metastasis and is commonly observed in tumor samples from head and neck cancer patients (37, 38) .
However, the precise molecular events that initiate this complex process of EMT in head and neck cancers are poorly understood. There is increasing evidence that suggests a dynamic interaction between cancer cells and the host microenvironment to support tumor growth and spread (39) . Stromal fibroblasts represent a major component of tumor microenvironment and soluble factors from mammary carcinoma-associated fibroblasts were shown to induce an EMT phenotype in PMC42-LA human breast carcinoma cells (40) . We have previously shown that head and neck tumors exhibit significantly higher levels of Bcl-2 expression in tumor associated endothelial cells (27) and overexpression of Bcl-2 alone in tumor-associated endothelial cells was sufficient to enhance tumor metastasis of oral squamous cell carcinoma in a SCID mouse model (25) .
In this study, we show that endothelial cells expressing Bcl-2 (EC-Bcl-2), when co- al, showed that IL-6 induces a complex reciprocally regulated cytokine network in tumor cells which leads to the development of malignant and invasive tumors in a human skin carcinoma model (29) . Interestingly, we also have previously observed that multiple Nuclear Factor-κB related serum cytokines (IL-6, IL-8, VEGF, HGF and Gro-α) are strongly associated with poor prognosis in HNSCC patients (42) . Out of these cytokines/chemokines, IL-6 was an independent predictor of tumor recurrence, poor survival and tumor metastasis (30, 31) . In addition to IL-6, HGF has also been shown to regulate cell scattering and tumor metastasis in HNSCC (43) .
Therefore, we designed this study to further understand the role and mechanism(s) of IL- 
that has demonstrated that IL-6 can induce EMT changes in immortalized oral epithelial cells and head and neck tumor cells.
We validated our in vitro results by implanting IL-6 overexpressing tumor cells (CAL27-IL-6) in SCID mice. Interestingly, IL-6 overexpression alone was enough to transform a nonmetastatic cell line (CAL27) into a metastatic cell line. It is possible that IL-6 mediated EMT changes may also contribute to subsequent steps of the metastatic cascade (e.g. anoikis resistance), as EMT-specific genes are known to play an important role in these metastatic steps (47, 48) . Taken together, our results provide novel insight into the role of IL-6 in HNSCC that could explain the direct correlation observed between high serum IL-6 levels and tumor metastasis in head and neck cancer patients. 
